Author:
Babadjouni Robin Moshe,Radwanski Ryan E,Walcott Brian P,Patel Arati,Durazo Ramon,Hodis Drew M,Emanuel Benjamin A,Mack William J
Abstract
Intracerebral hemorrhage and, more specifically, intraparenchymal hemorrhage, are devastating disease processes with poor clinical outcomes. Primary injury to the brain results from initial hematoma expansion while secondary hemorrhagic injury occurs from blood-derived products such as hemoglobin, heme, iron, and coagulation factors that overwhelm the brains natural defenses. Novel neuroprotective treatments have emerged that target primary and secondary mechanisms of injury. Nonetheless, translational application of neuroprotectants from preclinical to clinical studies has yet to show beneficial clinical outcomes. This review summarizes therapeutic agents and neuroprotectants in ongoing clinical trials aimed at targeting primary and secondary mechanisms of injury after intraparenchymal hemorrhage.
Funder
National Institutes of Health
Subject
Clinical Neurology,General Medicine,Surgery
Reference93 articles.
1. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis;van Asch;Lancet Neurol,2010
2. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century;Feigin;Lancet Neurol,2003
3. High stroke incidence in the prospective community-based L’Aquila registry (1994–1998);Carolei;Stroke,1997
4. Epidemiology of intracerebral haemorrhage;Poon;New Insights in Intracerebral Hemorrhage. 37: Karger Publishers,2016
5. Intracerebral hemorrhage: a common and devastating disease in need of better treatment;Fiorella;World Neurosurg,2015
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献